Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lincare Holdings Inc.
Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering
November 9th, 2007
Lincare Holdings Inc. (NASDAQ:LNCR) announced the pricing of $250 million principal amount of convertible senior debentures due 2037 - Series A (the "Series A Debentures") and $250 million principal amount of convertible senior debentures due 2037 - Series B (the "Series B Debentures" and together with the Series A Debentures, the "Debentures"), in each case to be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lincare granted the initial purchasers of the Debentures an option to purchase an additional $25 million aggregate principal amount of the Series A Debentures and an option to purchase an...
Source: Biotech Law Weekly (2007-11-09)
|
|
Advertisement |
|
|
|
